Tag: COVID-19 and Monoclonal Antibodies

Ask the Doctor Question: CLL patients tend to have reactions to monoclonal antibodies (my experience is with Rituxan) typically during their first infusion. With the development of the monoclonal antibody infusions for COVID, and the ones involved in the PROVENT

Ask the Doctor Question: My question relates to certain reactions/side-effects to the Booster shot received 8/21/2021, not experienced previously with Pfizer doses 1 and 2 received in January/February 2021: Extreme fatigue, lack of energy, appetite, feeling out of sorts was

Ask the Doctor Question: I had four successive adverse “anaphylactoid” reactions to rituximab, (as part of a Fludarabine-Rituximab protocol here in Vancouver, Canada) before that treatment was abandoned. Am I at greater than usual risk of anaphylactoid reaction to the

Ask the Doctor Question: Does taking ibrutinib inhibit, neutralize, or degrade the ability of antibodies (being) produced by REGEN-COV? Answer: No, it does not. This is because the antibodies found in the REGEN-COV infusion are already made and being directly injected

Ask the Doctor Question: During CLL Society’s COVID Virtual Community meeting on 9/24, did I understand Dr. Lamanna to say she is routinely giving her CLL patients prophylactic pre-exposure monoclonal antibody infusions? If so, can I get this from my oncologist?

Ask the Doctor Question: Since there now are a few treatments under way for the pre-exposure prophylaxis treatment for high-risk patients, such as AZD7442, Regeneron and the upcoming Molnupirar, is there some data (even if limited) regarding the medical advice

Ask the Doctor Question: When do you except the FDA to approve monoclonal antibody therapy for CLL patients? Answer: We are monitoring the situation closely and have been in contact with FDA officials behind the scenes to push them to make